Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.44% | -19.99% | |||
| Gross Profit | -14.44% | 19.99% | |||
| SG&A Expenses | -9.29% | -8.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.01% | -15.76% | |||
| Operating Income | -5.01% | 15.76% | |||
| Income Before Tax | -6.56% | 23.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.56% | 23.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.56% | 23.64% | |||
| EBIT | -5.01% | 15.76% | |||
| EBITDA | -5.19% | 16.01% | |||
| EPS Basic | 7.98% | 11.65% | |||
| Normalized Basic EPS | 7.97% | 2.39% | |||
| EPS Diluted | 8.87% | 11.40% | |||
| Normalized Diluted EPS | 7.97% | 2.39% | |||
| Average Basic Shares Outstanding | 15.80% | -13.55% | |||
| Average Diluted Shares Outstanding | 15.80% | -13.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||